Kerendia FDA Approval Status
The U.S. Food and Drug Administration (FDA) approved Kerendia (finerenone) on July 8, 2021 [1]. Kerendia is a non-steroidal mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decrease in estimated glomerular filtration rate, kidney failure, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with type 2 diabetes [1].
How Does Kerendia Work?
Kerendia functions by blocking the detrimental effects of overactive mineralocorticoid receptors (MR). In patients with CKD and type 2 diabetes, these receptors can be overstimulated, leading to inflammation and fibrosis in the kidneys and heart [2]. By inhibiting these receptors, Kerendia helps to protect these organs from further damage.
What is the Active Ingredient in Kerendia?
The active ingredient in Kerendia is finerenone [1].
What Are the Potential Side Effects of Kerendia?
Common side effects reported with Kerendia include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [2]. Patients are advised to have their potassium levels monitored regularly [2].
Who Should Not Take Kerendia?
Kerendia is contraindicated in patients who are taking strong CYP3A4 inhibitors [1]. Additionally, individuals with certain adrenal insufficiency conditions may not be suitable for this medication [1].
What Are the Alternatives to Kerendia for CKD in Type 2 Diabetes?
While Kerendia offers a new therapeutic approach, other management strategies for CKD in type 2 diabetes include glycemic control with agents like SGLT2 inhibitors and GLP-1 receptor agonists, blood pressure management with ACE inhibitors or ARBs, and lifestyle modifications [3]. The optimal treatment plan is individualized.
When Did Kerendia Become Available?
Following FDA approval on July 8, 2021, Kerendia became available for patients [1].
What Are the Clinical Trial Results Supporting Kerendia's Approval?
The FDA's decision was based on data from clinical trials, including the FIDELIO-DKD and FIGARO-DKD studies, which demonstrated Kerendia's efficacy in reducing kidney and cardiovascular events in the target patient population [2].
What is the Patient Population for Kerendia?
Kerendia is approved for adult patients with chronic kidney disease (CKD) associated with type 2 diabetes [1].
Are There Generic Versions of Kerendia?
As of its approval in 2021, Kerendia was a new molecular entity, and generic versions were not available [1]. Information regarding future generic availability can be tracked on sites like DrugPatentWatch.com [4].
What is the Regulatory Pathway for Drugs Like Kerendia?
Drugs like Kerendia undergo rigorous review by the FDA, including assessment of safety and efficacy data from clinical trials, before receiving marketing approval [1].
Sources
1. U.S. Food & Drug Administration (FDA). (n.d.). FDA Approves Kerendia (finerenone) to Treat Adults With Chronic Kidney Disease Associated With Type 2 Diabetes. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-kerendia-finerenone-treat-adults-chronic-kidney-disease-associated-type-2-diabetes
2. Bayer. (n.d.). Kerendia® (finerenone). Retrieved from https://www.kerendia.com/
3. National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Diabetes and Chronic Kidney Disease. Retrieved from https://www.niddk.nih.gov/health-information/kidney-disease/diabetes
4. DrugPatentWatch.com. (n.d.). Kerendia Patent Information. Retrieved from https://drugpatentwatch.com/